Literature DB >> 18510668

Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial.

M A Ghannoum1, L A Wraith, B Cai, J Nyirady, N Isham.   

Abstract

BACKGROUND: Our group, in collaboration with seven other laboratories, has recently developed a method to determine the susceptibility of dermatophytes.
OBJECTIVES: The objective of this study was to determine the terbinafine susceptibility profile of dermatophyte isolates obtained from patients with tinea capitis enrolled in two large worldwide clinical trials and to investigate whether these susceptibilities differ by geographical location. Methods Susceptibilities were determined according to the Clinical and Laboratory Standards Institute M38-A2 standard.
RESULTS: From a total of 978 baseline dermatophyte isolates, we selected 301 isolates at random. These included: Trichophyton tonsurans (n = 125), Microsporum canis (n = 94), T. violaceum (n = 63) and M. audouinii (n = 19). The terbinafine minimum inhibitory concentration (MIC) range was 0.001-0.25 microg mL(-1), while MIC(50) and MIC(90) ranged between 0.002 and 0.125 microg mL(-1) and 0.03 and 0.25 microg mL(-1), respectively, for all species tested. MIC(50) and MIC(90) varied by individual species; however, there was no difference in terbinafine MIC among the different species isolated from U.S. and non-U.S. sites.
CONCLUSION: Terbinafine demonstrates potent antifungal activity against dermatophyte isolates obtained from patients with tinea capitis worldwide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18510668     DOI: 10.1111/j.1365-2133.2008.08648.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  8 in total

Review 1.  Fungi on the skin: dermatophytes and Malassezia.

Authors:  Theodore C White; Keisha Findley; Thomas L Dawson; Annika Scheynius; Teun Boekhout; Christina A Cuomo; Jun Xu; Charles W Saunders
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

2.  Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran.

Authors:  Saham Ansari; Mohammad T Hedayati; Kamiar Zomorodian; Keyvan Pakshir; Hamid Badali; Abdollah Rafiei; Mostafa Ravandeh; Seyedmojtaba Seyedmousavi
Journal:  Mycopathologia       Date:  2015-09-14       Impact factor: 2.574

3.  NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans.

Authors:  J Pannu; A McCarthy; A Martin; T Hamouda; S Ciotti; A Fothergill; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2009-05-11       Impact factor: 5.191

4.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

5.  A foot in the door for dermatophyte research.

Authors:  Rebecca Rashid Achterman; Theodore C White
Journal:  PLoS Pathog       Date:  2012-03-29       Impact factor: 6.823

Review 6.  Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review.

Authors:  Alok Kumar Sahoo; Rahul Mahajan
Journal:  Indian Dermatol Online J       Date:  2016 Mar-Apr

7.  Low in vitro activity of sertaconazole against clinical isolates of dermatophyte.

Authors:  Mahsa Behnam; Hossein Zarrinfar; Mohammad Javad Najafzadeh; Ali Naseri; Lida Jarahi; Monika Novak Babič
Journal:  Curr Med Mycol       Date:  2020

Review 8.  Therapy and Antifungal Susceptibility Profile of Microsporum canis.

Authors:  Chioma I Aneke; Domenico Otranto; Claudia Cafarchia
Journal:  J Fungi (Basel)       Date:  2018-09-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.